Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The study is to investigate the safety and efficacy of Zanubrutinib combined with
Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell
lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.